“Our move to the OTCQX will enable to company to continue a transparent trading and information experience for investors at a lower cost, while our management team focuses on growing the business and delivering long-term value to shareholders,” said CEO Dan Goldberger.
Here are five quick facts about the switch:
• Common stock trading on NYSE was suspended, according to a NYSE Regulation staff notice.
• NYSE Regulation previously delisted the company.
• Bacterin appealed NYSE Regulation’s decision to delist.
• Current financial disclosures and Real-Time Level 2 quotes for Bacterin are available to investors on OTCMarkets.com
• As of April 8, the company had a market cap of $28.07 million.
More articles on orthopedic devices:
6 spine, orthopedic device company mergers & acquisitions
Safe Orthopaedics launches fenestrated screw in Europe
Atlas Spine to raise $5M through OfferBoard—5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
